ATS Medical Inc. (ATSI) Awarded FDA-Approval for Cardiac Study of Aortic Valve Replacement

In the company’s news yesterday,

ATS Medical Inc. announced FDA-approval for a first-of-its-kind clinical study in which cardiac surgeons will implant ATS Medical’s ATS 3f® Aortic Bioprosthesis in patients under the age of 60, a population not yet studied in a controlled and scientific manner.

Astrid Berthe, vice president of Regulatory Affairs, said the FDA’s decision is a milestone that will raise the bar in aortic valve replacement.

“We are encouraged by the FDA approval to pursue this landmark opportunity in an approved post-market study with the ATS 3f Aortic Bioprosthesis in a younger patient population. We look forward to the outcomes that will demonstrate scientifically that the ATS 3f Aortic Bioprothesis is the highest performing tissue valve available to all patients in need of aortic valve replacement,” Berthe stated in the press release.

The ATS 3f® Aortic Bioprosthesis is designed to replace and function as a “native” aortic valve. The valve is tubular in design, allowing for flexibility when external pressure is applied, restoring blood flow and the natural stress distribution to the aortic root.

Targeting a younger and more active patient roster, ATS Medical anticipates the study to demonstrate the safety and efficacy of the ATS 3f Aortic Bioprostheis, ultimately providing the durability needed for patients to maintain their active lifestyles after heart surgery.

The company said it is now reviewing and discussing hospital discussion and will begin patient enrollment after it receives Institutional Review Board approval for each facility.

About QualityStocks

QualityStocks, based in Scottsdale, Arizona is a free service that collects data from hundreds Small-Cap and Micro-Cap online Investment Newsletters into one Free Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their advertising efforts and now has over 750,000+ subscribers that receive The Daily Stock Newsletters.

Please see disclaimer on QualityStocks website: http://Disclaimer.QualityStocks.net 

Forward-Looking Statement:

This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.